264 related articles for article (PubMed ID: 30081001)
21. The mTORC1 inhibitor rapamycin and the mTORC1/2 inhibitor AZD2014 impair the consolidation and persistence of contextual fear memory.
MacCallum PE; Blundell J
Psychopharmacology (Berl); 2020 Sep; 237(9):2795-2808. PubMed ID: 32601986
[TBL] [Abstract][Full Text] [Related]
22. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
23. Everolimus inhibits PI3K/Akt/mTOR and NF-kB/IL-6 signaling and protects seizure-induced brain injury in rats.
Huang XY; Hu QP; Shi HY; Zheng YY; Hu RR; Guo Q
J Chem Neuroanat; 2021 Jul; 114():101960. PubMed ID: 33915267
[TBL] [Abstract][Full Text] [Related]
24. Advances in the mTOR signaling pathway and its inhibitor rapamycin in epilepsy.
Zhao W; Xie C; Zhang X; Liu J; Liu J; Xia Z
Brain Behav; 2023 Jun; 13(6):e2995. PubMed ID: 37221133
[TBL] [Abstract][Full Text] [Related]
25. Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice.
Hampel P; Römermann K; Gailus B; Johne M; Gericke B; Kaczmarek E; Löscher W
Neuropharmacology; 2021 Mar; 185():108449. PubMed ID: 33450274
[TBL] [Abstract][Full Text] [Related]
26. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy.
Russo E; Citraro R; Donato G; Camastra C; Iuliano R; Cuzzocrea S; Constanti A; De Sarro G
Neuropharmacology; 2013 Jun; 69():25-36. PubMed ID: 23092918
[TBL] [Abstract][Full Text] [Related]
27. Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia.
Leitner DF; Kanshin E; Askenazi M; Siu Y; Friedman D; Devore S; Jones D; Ueberheide B; Wisniewski T; Devinsky O
PLoS One; 2022; 17(5):e0268597. PubMed ID: 35587487
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures.
Töllner K; Twele F; Löscher W
Epilepsy Behav; 2016 Apr; 57(Pt A):95-104. PubMed ID: 26930359
[TBL] [Abstract][Full Text] [Related]
29. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
30. The Search for New Screening Models of Pharmacoresistant Epilepsy: Is Induction of Acute Seizures in Epileptic Rodents a Suitable Approach?
Löscher W
Neurochem Res; 2017 Jul; 42(7):1926-1938. PubMed ID: 27502939
[TBL] [Abstract][Full Text] [Related]
31. (
Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
[TBL] [Abstract][Full Text] [Related]
32. Potentiation of the anticancer effects of everolimus using a dual mTORC1/2 inhibitor in hepatocellular carcinoma cells.
Kim JO; Kim KH; Song IS; Cheon KS; Kim OH; Lee SC; Lee SK; Kim SJ
Oncotarget; 2017 Jan; 8(2):2936-2948. PubMed ID: 27935857
[TBL] [Abstract][Full Text] [Related]
33. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy.
Klitgaard H; Matagne A; Gobert J; Wülfert E
Eur J Pharmacol; 1998 Jul; 353(2-3):191-206. PubMed ID: 9726649
[TBL] [Abstract][Full Text] [Related]
34. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
36. Blockade of endothelin B receptor improves the efficacy of levetiracetam in chronic epileptic rats.
Ko AR; Kang TC
Seizure; 2015 Sep; 31():133-40. PubMed ID: 26362390
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.
Overwater IE; Rietman AB; Bindels-de Heus K; Looman CW; Rizopoulos D; Sibindi TM; Cherian PJ; Jansen FE; Moll HA; Elgersma Y; de Wit MC
Neurology; 2016 Sep; 87(10):1011-8. PubMed ID: 27511181
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
39. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
40. Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
Aronica E; Specchio N; Luinenburg MJ; Curatolo P
Brain; 2023 Jul; 146(7):2694-2710. PubMed ID: 36806388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]